Pulmatrix Raises $14M for PUR118 Phase II Trials

Pulmatrix raised $14 million to progress its lead inhaled cationic airway lining modulator drug candidate.

Respiratory disease therapeutics firm Pulmatrix raised $14 million in a Series B1 round of financing to progress its lead inhaled cationic airway lining modulator (iCALM) drug candidate, PUR118, through Phase II trials in the treatment of both COPD and cystic fibrosis (CF).

Phase Ib studies with the inhaled dry powder-formulated PUR118 have recently been initiated for the COPD indication. A clinical study evaluating PUR118 in CF patients is planned for the near future.

Pulmatrix’ iCALM platform is designed to stimulate the lung’s natural defense mechanisms to prevent infection, enhance the clearance of pathogens, and reduce airway inflammation. Rather than center on the development of single treatments for individual pathogens, effectively the “